Serrano-Gallardo G, Magallanes-Quintana R, Godoy-Rábago G, Muruato-Ontiveros E, López TAP, Hidalgo-Vidal J

Idioma: Ingles.
Referencias bibliográficas: 9
Paginas: 42-46
Archivo PDF: 1567.96 Kb.

RESUMEN

La colocación de válvulas aórticas percutáneas ha pasado de ser un procedimiento para pacientes quirúrgicos de alto riesgo a un procedimiento aceptado en 2019 por la FDA para pacientes de riesgo medio y bajo a nivel mundial. La mayoría de las endocarditis posteriores a TAVI se presentan antes del primer año del procedimiento. Su incidencia es de 0.5 a 2%. Presentamos dos casos de endocarditis infecciosa temprana postreemplazo valvular aórtico transcatéter en dos casos de bajo riesgo quirúrgico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rodríguez-Vidigal FF, Nogales-Asensio JM, Calvo-Cano A, González-Fernández R, Martínez-Carapeto A, Gómez-Sanchez I, et al. Infective endocarditis after transcatheter aortic valve implantation: Contributions of a single-centre experience on incidence and associated factors. Enferm Infecc Microbiol Clin (Engl Ed). 2019;37(7):428-434. doi: 10.1016/j.eimc.2018.09.009.

2. Ascione G, Denti P. New challenges in the era of low-intermediate risk transcatheter aortic valve replacement: surgery for infective endocarditis. Eur J Cardiothorac Surg. 2022;62(1):ezac150. doi: 10.1093/ejcts/ezac150.

3. FDA expands indication for several transcatheter heart valves to patients at low risk for death or major complications associated with open-heart surgery. (2019, 16 de agosto). fda.gov. https://www.fda.gov/news-events/press-announcements/fda-expands-indication-several-transcatheter-heart-valves-patients-low-risk-death-or-major.

4. Kim H, Kang DY, Ahn JM, Kim JB, Yeung AC, Nishi T, et al. Race-specific impact of conventional surgical risk score on 1-year mortality after transcatheter aortic valve replacement. JACC Asia. 2023;3(3):376-387. doi: 10.1016/j.jacasi.2022.11.007.

5. Fagu A, Siepe M, Uzdenov M, Dees D, Kondov S, Beyersdorf F, et al. Subsequent cardiac surgery after transcatheter aortic valve implantation: Indications and outcomes. J Card Surg. 2022;37(12):5187-5194. doi: 10.1111/jocs.17219.

6. Del Val D, Panagides V, Mestres CA, Miró JM, Rodés-Cabau J. Infective endocarditis after transcatheter aortic valve replacement: JACC state-of-the-art review. J Am Coll Cardiol. 2023;81(4):394-412. doi: 10.1016/j.jacc.2022.11.028.

7. Ogami T, Ridgley J, Serna-Gallegos D, Kliner DE, Toma C, Sanon S, et al. Outcomes of surgical aortic valve replacement after transcatheter aortic valve implantation. Am J Cardiol. 2022;182:63-68. doi: 10.1016/j.amjcard.2022.07.026.

8. Bapat VN, Zaid S, Fukuhara S, Saha S, Vitanova K, Kiefer P, et al. Surgical explantation after TAVR failure: mid-term outcomes from the EXPLANT-TAVR International Registry. JACC Cardiovasc Interv. 2021;14(18):1978-1991. doi: 10.1016/j.jcin.2021.07.015.

9. Modine T, Corona S, Mack M. TAVI: from concept to success. The story from a surgeon's point of view. Thoughts from three generations. Arch Cardiovasc Dis. 2022;115(4):231-234. doi: 10.1016/j.acvd.2022.04.003.